Although teatment with spironolactone, RAAS and ACE inhibitors has been shown to provide cardiovascular benefit and reduce mortality in patients with heart failure [10]–[12], these drugs also have an increased risk of hyperkalemia. This evidence concerns the gene ACE and Hyperkalemia.